NAD+: Published Research

Introduction

The published research literature on NAD+ spans multiple disciplines: classical biochemistry, molecular biology, clinical pharmacology, and translational medicine. The body of evidence can be broadly organized into three categories. First, mechanistic cell-biology and animal studies that characterized the roles of NAD+ in sirtuin-dependent deacylation, PARP-dependent DNA repair, and redox metabolism. Second, preclinical studies demonstrating that manipulating the NAD+ pool — by inhibiting consuming enzymes or supplying biosynthetic precursors — produces measurable changes in cellular phenotypes in model organisms. Third, human clinical studies that have investigated the pharmacokinetics and safety of oral NAD+ precursors, with a smaller number examining functional metabolic outcomes.

This article summarizes findings from each category, with full attribution to primary sources. Findings from preclinical models do not establish safety or efficacy in humans. SpartaLabs makes no claims about the use of this compound.

Methodology Types in the Literature

The NAD+ research corpus employs mechanistic cell-culture studies, rodent genetic models, and human clinical trials — each with distinct strengths and interpretive limits. Human trials have primarily used surrogate endpoints such as whole-blood or PBMC NAD+ concentrations, because direct tissue-level measurements require invasive biopsy; this is an acknowledged measurement boundary the field is actively working to resolve. Key analytical tools include mass spectrometry-based metabolomics for NAD+ metabolome quantification, RNA sequencing for transcriptomic profiling, and hyperinsulinemic-euglycemic clamp studies for insulin sensitivity measurement. The molecular mechanisms underlying these research findings — including sirtuin substrate consumption and the NAMPT salvage pathway — are detailed in the NAD+ mechanism of action article.

Summary of Key Preclinical Studies

Sirtuin–NAD+ Coupling (Imai et al., 2000)

The foundational demonstration that sirtuin enzymatic activity is obligately NAD+-dependent was reported by Imai, Armstrong, Kaeberlein, and Guarente in Nature in 2000 [1]. Using biochemical and genetic approaches in Saccharomyces cerevisiae, the authors demonstrated that Sir2, the founding member of the sirtuin family, catalyzes a reaction in which NAD+ is consumed stoichiometrically in proportion to each deacetylation event. Mutant Sir2 enzymes that retained histone-binding but lacked NAD-binding capacity lost deacetylase activity, establishing NAD+ dependency as catalytically essential rather than regulatory. This work set the conceptual framework for subsequent research into NAD+ as a metabolic signal upstream of epigenetic regulation.

PARP1 and SIRT1 Competition for NAD+ (Bai et al., 2011)

Bai, Cantó, and colleagues reported in Cell Metabolism in 2011 that genetic deletion of PARP1 in mice was associated with elevated tissue NAD+ concentrations, increased SIRT1 deacetylase activity, and altered mitochondrial gene expression patterns [2]. Pharmacological PARP inhibition in wild-type mice produced similar NAD+ and SIRT1 changes. The authors interpreted these findings as evidence that PARP1 and SIRT1 compete for the same intracellular NAD+ pool, and that the balance of consumption between these two enzymes influences downstream metabolic phenotypes. This mechanistic study established a framework for understanding how competing NAD+-consuming enzymes interact, and was conducted exclusively in rodent models.

NAD+ Decline and Nuclear-Mitochondrial Communication (Gomes et al., 2013)

Gomes, Price, Ling, and colleagues — working in the Sinclair laboratory at Harvard — reported in Cell in 2013 that aged mouse tissues showed altered NAD+ concentrations relative to young controls, and that this was associated with reduced SIRT1 activity, nuclear accumulation of HIF-1α under normoxic conditions, and a disrupted expression ratio of mitochondria-encoded versus nuclear-encoded subunits of the oxidative phosphorylation complexes [3]. The authors characterized this state as "pseudohypoxic." Administering the NAD+ precursor NMN to aged mice was associated in that study with partial normalization of the mitochondrial gene expression signatures — the finding that drew the most scientific attention and has informed subsequent preclinical and clinical work. This study was conducted in a rodent model.

NR and Mitochondrial Biology in Rodents (Cantó et al., 2012)

Cantó and colleagues reported in Cell Metabolism in 2012 that dietary supplementation with nicotinamide riboside (NR) in mice produced dose-dependent elevation of hepatic and muscle NAD+ concentrations, activation of SIRT1 and SIRT3 as measured by substrate deacetylation, and altered mitochondrial acetylation patterns [4]. NR-supplemented mice showed different metabolic parameters relative to control animals. SIRT1-deficient mice did not show the same responses, which the authors used to support the interpretation that NR's observed effects in that model were SIRT1-mediated. These findings were preclinical; human translation was not addressed in the original study.

Summary of Human Clinical Studies

NR Pharmacokinetics in Humans (Trammell et al., 2016)

The first human pharmacokinetic study of oral NR was reported by Trammell, Schmidt, Weidemann, and colleagues — with Brenner as senior author — in Nature Communications in 2016 [5]. In a dose-escalation study followed by a small multi-subject cohort, the authors documented dose-dependent increases in whole-blood NAD+ following oral NR. A reported peak increase of approximately 2.7-fold was observed at the highest dose in one subject. The study also documented that nicotinic acid adenine dinucleotide (NAAD) — not previously thought to be an intermediate in the NR-to-NAD+ conversion pathway — appeared as a sensitive marker of NR-induced NAD+ repletion. This finding revealed a more complex metabolic routing than had been previously described and provided a validated biomarker for subsequent human studies.

NR in Healthy Older Adults: Safety and NAD+ Elevation (Martens et al., 2018)

Martens, Denman, Mazzo, and colleagues published a randomized, double-blind, placebo-controlled, crossover trial in Nature Communications in 2018, enrolling 24 healthy adults aged 55 to 79 years [6]. Whole-blood NAD+ was reported to increase by approximately 60% during the NR treatment period relative to baseline. In addition, the authors reported reductions in systolic blood pressure and certain measures of aortic stiffness in participants with elevated baseline systolic blood pressure. The trial was not designed to establish a causal mechanism connecting NAD+ elevation to these cardiovascular measurements, and the authors identified these observations as warranting investigation in larger, specifically designed trials.

NR in Aged Skeletal Muscle (Elhassan et al., 2019)

Elhassan, Philp, Lavery, and colleagues reported in Cell Reports in 2019 the results of a placebo-controlled, randomized, double-blind, crossover trial in 12 aged men who received NR for 21 days [7]. Skeletal muscle biopsies analyzed by targeted metabolomics confirmed that NR elevated NAD+ metabolome concentrations in muscle tissue, as evidenced by accumulation of downstream metabolite species — an advance over prior studies that had relied on blood-based measurements. RNA sequencing identified NR-associated transcriptomic changes in pathways related to energy metabolism. The authors also noted that mitochondrial respiratory capacity, measured by high-resolution respirometry, did not differ significantly between NR and placebo periods, characterizing the divergence between transcriptomic and functional phenotypes as a question to be resolved by subsequent work.

NMN in Prediabetic Women (Yoshino et al., 2021)

Yoshino and colleagues from Washington University in St. Louis published a randomized, double-blind, placebo-controlled trial in Science in 2021, investigating NMN supplementation in 25 overweight and obese postmenopausal women with prediabetes [8]. Hyperinsulinemic-euglycemic clamp assessment demonstrated that insulin-stimulated skeletal muscle glucose disposal was greater following NMN treatment than following placebo — a direct measurement of an insulin-sensitivity endpoint using a gold-standard metabolic research technique. RNA sequencing of muscle biopsies identified NMN-associated changes in the expression of genes related to muscle remodeling. Whole-blood NAD+ concentrations were elevated in the NMN group relative to placebo. The authors noted that findings from this specific population should be evaluated alongside studies in other demographic groups before generalizing.

NR in Obese Men (Dollerup et al., 2018)

Dollerup, Christensen, Svart, and colleagues reported in the American Journal of Clinical Nutrition in 2018 a randomized, placebo-controlled trial of NR supplementation at high doses for 12 weeks in 40 sedentary obese men [9]. The primary outcome was insulin sensitivity measured by hyperinsulinemic-euglycemic clamp. The authors reported that the primary insulin-sensitivity endpoint did not reach statistical significance between NR and placebo groups, while noting that no serious adverse events were attributed to NR — contributing to the overall safety data for the compound. Secondary outcome measures including resting energy expenditure, lipolysis, lipid oxidation, and body composition also did not differ significantly. The authors discussed these findings in the context of the broader literature, noting that differences between population characteristics (sedentary obese men versus the rodent or prediabetic populations in other studies) may be a relevant variable for subsequent research design.

Active Research Frontier

Heterogeneity in published human trial results — some studies reporting metabolic effects, others reporting null primary endpoints — is informative for the next generation of study design, directing attention toward population-specific factors such as age, sex, metabolic status, and baseline NAD+ levels. The NR-SAFE trial (2023) demonstrated that magnetic resonance spectroscopy can detect NAD+ changes in human brain tissue non-invasively, a methodological advance with implications for neurological research applications. A 2023 systematic review by Gaspar and colleagues in the American Journal of Physiology-Endocrinology and Metabolism evaluated the published clinical evidence base and identified larger, longer-duration trials as the field's central research priority [10] — a call reflected in active clinical registrations spanning cardiovascular disease, Parkinson's disease, non-alcoholic fatty liver disease, and COVID-19 sequelae. The role of related antioxidant systems in this metabolic research context has also been investigated in parallel work, including published research on glutathione, an endogenous tripeptide antioxidant whose cellular redox interactions intersect with NAD+ biology. NAD+ from SpartaLabs is supplied as independently verified, research-grade material with batch-specific certificate of analysis documentation.

References

1. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800. DOI: 10.1038/35001622. https://pubmed.ncbi.nlm.nih.gov/10693811/

2. Bai P, Cantó C, Oudart H, Brunyánszki A, Cen Y, Thomas C, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011;13(4):461–468. DOI: 10.1016/j.cmet.2011.03.004. https://pubmed.ncbi.nlm.nih.gov/21459330/

3. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624–1638. DOI: 10.1016/j.cell.2013.11.037. https://pubmed.ncbi.nlm.nih.gov/24360282/

4. Cantó C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15(6):838–847. PMC3616313. https://pmc.ncbi.nlm.nih.gov/articles/PMC3616313/

5. Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. DOI: 10.1038/ncomms12948. https://www.nature.com/articles/ncomms12948

6. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMC5882464. https://pubmed.ncbi.nlm.nih.gov/29599478/

7. Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28(7):1717–1728.e6. DOI: 10.1016/j.celrep.2019.07.043. https://pubmed.ncbi.nlm.nih.gov/31412242/

8. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. DOI: 10.1126/science.abe9985. https://pubmed.ncbi.nlm.nih.gov/33888596/

9. Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343–353. DOI: 10.1093/ajcn/nqy132. https://pubmed.ncbi.nlm.nih.gov/29992272/

10. Gaspar LS, Álvaro AR, Moita J, Cavadas C. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. Am J Physiol Endocrinol Metab. 2023;325(5):E451–E465. DOI: 10.1152/ajpendo.00242.2023. https://journals.physiology.org/doi/full/10.1152/ajpendo.00242.2023